Tetralogy of Fallot (TOF), the most common severe congenital heart malformation, occurs sporadically, without other anomaly, and from unknown cause in 70% of cases. Through a genome-wide survey of 114 subjects with TOF and their unaffected parents, we identified 11 de novo copy number variants (CNVs) that were absent or extremely rare (o0.1%) in 2,265 controls. We then examined a second, independent TOF cohort (n ¼ 398) for additional CNVs at these loci. We identified CNVs at chromosome 1q21.1 in 1% (5/512, P ¼ 0.0002, OR ¼ 22.3) of nonsyndromic sporadic TOF cases. We also identified recurrent CNVs at 3p25.1, 7p21.3 and 22q11.2. CNVs in a single subject with TOF occurred at six loci, two that encode known (NOTCH1, JAG1) diseaseassociated genes. Our findings predict that at least 10% (4.5-15.5%, 95% confidence interval) of sporadic nonsyndromic TOF cases result from de novo CNVs and suggest that mutations within these loci might be etiologic in other cases of TOF.
Tetralogy of Fallot (TOF), the most common severe congenital heart malformation, occurs sporadically, without other anomaly, and from unknown cause in 70% of cases. Through a genome-wide survey of 114 subjects with TOF and their unaffected parents, we identified 11 de novo copy number variants (CNVs) that were absent or extremely rare (o0.1%) in 2,265 controls. We then examined a second, independent TOF cohort (n ¼ 398) for additional CNVs at these loci. We identified CNVs at chromosome 1q21.1 in 1% (5/512, P ¼ 0.0002, OR ¼ 22.3) of nonsyndromic sporadic TOF cases. We also identified recurrent CNVs at 3p25.1, 7p21.3 and 22q11.2. CNVs in a single subject with TOF occurred at six loci, two that encode known (NOTCH1, JAG1) diseaseassociated genes. Our findings predict that at least 10% (4.5-15.5%, 95% confidence interval) of sporadic nonsyndromic TOF cases result from de novo CNVs and suggest that mutations within these loci might be etiologic in other cases of TOF.
The combination of a malpositioned aorta that overrides both ventricles, ventricular septal defect, pulmonary stenosis (which obstructs blood flow into the lungs) and right ventricular hypertrophy ( Fig. 1) defines TOF. The most prevalent form of cyanotic heart disease, TOF occurs in one of 3,000 live births and accounts for 10% of all serious congenital heart disease 1 . With recent advances in corrective surgery, early lethality from TOF is rare, but long-term sequelae, including arrhythmia, ventricular dysfunction and often lifelong disability, persist.
TOF can arise in the context of prenatal infections, exposure to teratogens or maternal illness, and from dominant mutations that Figure 1 Anatomy and pathophysiology of tetralogy of Fallot. (a) Normal heart structure promotes unidirectional flow of deoxygenated blood (blue) into the lungs and oxygenated blood (red) into the aorta. (b) In TOF, pulmonary stenosis and narrowing of the right ventricular outflow tract (RVOT) impedes the flow of deoxygenated blood into the lungs, and both the ventricular septal defect (VSD) and overriding aorta (*) promote the flow of deoxygenated blood into the systemic circulation to produce cyanosis ('blue baby' syndrome). Right ventricular hypertrophy (RVH) is also present. (c) A Doppler echocardiogram shows mixing of deoxygenated blood from the right ventricle (RV) and oxygenated blood from the left ventricle (LV) as blood is pumped out the overriding aorta (Ao) in an individual with TOF. RA, right atrium; LA, left atrium. Images from Multimedia Library of Congenital Heart Disease, Children's Hospital, Boston, Massachusetts (ed. R. Geggel, http:// www.childrenshospital.org/mml/cvp; used with permission). usually alter gene dosage. Haploinsufficiency of cardiac transcription factor genes (NKX2-5, TBX1, TBX5 and GATA4) or the transmembrane receptors NOTCH1 and NOTCH2 and their ligand JAG1 can cause TOF, but, more commonly, mutations in these genes produce other heart malformations [2] [3] [4] [5] [6] [7] . Cytogenetic abnormalities, including deletions of chromosome 22q11.2 (DiGeorge syndrome) or trisomy 21 (Down syndrome), account for 15% and 7% of TOF, respectively; however, these individuals usually have many noncardiac abnormalities 8, 9 . Large de novo CNVs identified by array CGH occur with major congenital anomalies 10, 11 ; these typically include congenital heart disease (CHD) in half of all cases 12 . Far less is known about genes that cause sporadic and isolated CHD, particularly genes involved in complex malformations.
We hypothesized that de novo mutations that alter the dosage of genes involved in cardiac development might account for isolated TOF. We surveyed the genome of 121 TOF trios, each comprised of one proband and two unaffected parents, using the Affymetrix 6.0 array ( Supplementary Fig. 1 ). CNVs identified in subjects with TOF but absent from parental samples using the algorithm Birdseye 13 (putative de novo CNVs) were studied further. CNVs that corresponded to known copy number polymorphisms (CNPs) 14 or that were smaller than 20 kb were discarded. To distinguish between potentially pathogenic variants and unidentified benign CNPs, we examined all putative de novo TOF CNVs in 2,265 controls genotyped on the Affymetrix 6.0 array (ref. 15 and unpublished data), and those TOF CNVs that shared Z50% overlap with CNVs found in Z0.1% of control samples were designated as CNPs and were not studied further. Seven individuals with an excess of rare de novo CNVs were removed from the analysis. Of the 32 remaining putative de novo CNVs, 11 were independently validated using multiplex ligationdependent probe amplification (MLPA) (Supplementary Table 1 ) and 21 (66%) were false positives, of which 12 CNVs were inherited and 9 CNVs could not be confirmed by MLPA (data not shown). In summary, genome-wide analyses and validation identified 11 rare de novo CNVs at 10 unique loci from 114 TOF trios.
We considered whether the frequency of de novo CNVs differed between subjects with TOF and healthy subjects by analyzing 98 control trios, including 55 HapMap trios, genotyped using the Affymetrix 6.0 array ( Supplementary Fig. 1 ). Using the same computational algorithm, we identified 20 putative de novo CNVs: 12 in HapMap trios and 8 in other control trios. Seven of the CNVs found in HapMap trios have been previously attributed to cell-line artifacts (chromosome 14:105829131-106116317 in NA10854, NA10838, NA06991, NA18857 and NA19154; chromosome 22:20777493-21581602 in NA12707 and NA19154) 16 , and two CNVs in HapMap trios and seven CNVs found in the other control trios fulfilled our criteria as CNPs. Four CNVs were validated by MLPA as being de novo in the control trios (Supplementary Table 2 ). The frequency of rare de novo CNVs was greater in TOF trios than in control trios, but the difference was not statistically significant (11/114 versus 4/98, P ¼ 0.18). Although de novo CNVs and pathogenesis seems to be related in schizophrenia 17, 18 and autism 19 , our trio study may be underpowered to detect a similar relationship in TOF. Alternatively, TOF mutations may be incompletely penetrant, a consideration that prompted us to assess whether inherited CNVs occurred at loci discovered by our de novo CNVs analyses. In three TOF trios, we identified CNVs at the 1q21.1, 3p25.1 and 7p21.3 loci that were inherited from unaffected parents ( Table 1) , a finding that supports the role of other genetic or environmental interactions in TOF.
To further evaluate the pathogenicity of CNVs, we used MLPA to assess nine loci in a second cohort of sporadic, nonsyndromic TOF cases (n ¼ 398). Because the subjects in this validation cohort had previous chromosome 22q11.2 analyses, we excluded this locus from further study. We designed at least two unique synthetic oligonucleotide MLPA probes (Supplementary Table 3 ) to hybridize within each of the nine loci. MLPA studies demonstrated four more subjects with TOF having 1q21.1 CNVs (three duplications, one deletion; Supplementary Table 1 ). The boundaries of these CNVs were delineated by Affymetrix 6.0 array analyses. In combination with our initial genomewide studies, we found a total of 17 CNVs at 10 loci in 512 individuals with TOF ( Table 1) . CNVs at each of these loci were absent or very rare in 2,265 controls. CNVs at four loci (1q21.1, 3p25.1, 7p21.3 and 22q11.2) were found in at least two individuals with TOF. Because small CNVs would be predicted to escape detection by the array platform and detection algorithm used here, our data define a minimum estimate, approximately 10% (11/114), for the frequency of de novo CNVs in sporadic, isolated TOF. This was lower than the 25%-30% frequency of de novo events seen in individuals with syndromic heart malformations that occur with additional birth defects 10, 11 , but, notably, identified causes for isolated TOF. At chromosome 1q21.1, we found CNVs that were structurally complex in five TOF cases (Fig. 2a,b) (Supplementary Fig. 2 ). The shared duplicated segment in four subjects with TOF spans a small interval on chromosome 1q21.1 where seven annotated genes are located: PRKAB2, PDIA3P, FMO5, CHD1L, BCL9, ACP6 and GJA5. Transcriptional analyses of human right ventricular outflow tract (RVOT), which is malformed in TOF, showed that six of these genes were expressed. Among these six genes, PRKAB2, CHD1L, BCL9 and GJA5 had the highest expression in RVOT (Table 2) , a finding that increases their candidacy as disease-associated genes. In 96 subjects with independent, sporadic TOF, we sequenced exons and flanking splice sites in GJA5 and CHD1L, which encode connexin 40 and chromodomain helicase DNA binding protein-1, respectively. We did not identify any nonsynonymous changes at conserved residues or small insertions/deletions (data not shown).
Chromosome 1q21.1 has been previously implicated in CHD 20 , but more recently CNVs at this locus were identified in subjects with neurocognitive, psychiatric and developmental phenotypes 17 .250) and a deletion in one subject (3701) overlapped a 875,266-bp region at 1q21 (chr1:144965244-145840510) that encompasses six known genes expressed in the human RVOT. Previously described duplications at this locus are associated with mental retardation (MR) 21 , TOF 16 , macrocephaly (MaC) 22 and other congenital phenotypes 23 . Studies have identified multiple individuals (number of individuals in parentheses; only the minimal overlapping region between individuals is shown) that carry deletions at this locus with congenital heart disease other than TOF (CHD), MR, schizophrenia (SCZ), microcephaly (MiC) or CHD and MR. (b) Plot showing normalized probe intensity measurements across 1q21 in the four subjects with TOF carrying a deletion (turquoise), the one subject with a duplication (green) and 273 copy number-neutral controls (gray lines) and summarized as mean (black) ± 2 Â median absolute deviation (dark blue lines). Notably, there is no perfect correlation between 1q21 dosage and phenotype in any study so far (including ours). Two studies described mild (seven cases) or severe (five cases, not including TOF) cardiovascular malformations, but nine of these individuals had additional phenotypes: developmental or intellectual disabilities, dysmorphic craniofacial features or other congenital anomalies 22, 23 . In contrast, all subjects with TOF with 1q21.1 CNVs identified in our study had normal cognition, social behavior and neurologic function ( Table 3) . The combination of structural heart malformations and functional (nonstructural) brain deficits caused by 1q21.1 rearrangements resembles the DiGeorge phenotype caused by chromosome 22q11.2 deletions that disrupt TBX1 (refs. 8, 9) . Although the variable length of 1q21.1 CNVs might imply that these mutations alter contiguous genes with distinct roles in cognition and heart development, we speculate that this locus contains a single causal gene that, like TBX1, functions in progenitor cells (perhaps neural crest cells) critical for both cardiovascular and brain development. Regardless of whether this explanation or another accounts for both clinical phenotypes, we note that less than 0.2% of individuals with neuropsychiatric disorders and 0.02% of controls had chromosome 1q21.1 duplications 23 . In contrast, 1q21.1 duplications were significantly (P ¼ 0.007) more common in TOF, occurring in 1% of cases studied here.
Two subjects with TOF shared overlapping duplications at the 3p25.1 locus. Whereas one duplication spanned 12 Mb, the other duplication affected only two genes, RAF1 and TMEM40 (Fig. 2c) . RAF1 is expressed approximately 100-fold more highly than TMEM40 in the RVOT ( Table 2) . Gain-of-function point mutations of RAF1 cause Noonan syndrome, a multisystem disorder with cardiac manifestations that rarely includes TOF but produces one of its components: hypertrophy, atrial or ventricular septal defects or pulmonary stenosis 27, 28 . Identification of CNVs at 3p25.1 in TOF cases prompted reevaluation for signs of Noonan syndrome ( Table 3) . Subtle craniofacial abnormalities were identified in one individual (subject 756), suggesting some phenotypic overlap between RAF1 gain-of-function mutations and increases in RAF1 copy number produced by the 12-Mb duplication. The smaller 3p25.1 CNV truncates and duplicates RAF1, and further study is necessary to determine which alteration causes the TOF phenotype.
We found reciprocal CNVs at 7p21.3 in two subjects with TOF. No known genes, mRNAs, microRNAs or ESTs are encoded at this locus ( Supplementary Fig. 3) ; ongoing RVOT transcript analyses and resequencing may help identify the target of these CNVs.
Chromosome 22q11.2 deletions were identified in two individuals with TOF who lacked any extracardiac phenotype that accompanies DiGeorge syndrome 29 . We also found a large 22q11.2 deletion in one control subject. These data are consistent with incomplete penetrance of 22q11.2 deletions 30 . Whether genetic mechanisms that compensate for the deleterious consequence of 22q11.2 deletions also influence other CNVs is unknown.
Of six de novo CNVs found in only one individual with TOF, two altered previously described congenital heart disease-associated genes, NOTCH1 and JAG1. NOTCH1 null mutations primarily cause familial bicuspid aortic valve and less commonly other 
10q11. 21 No genes 0 CNV, cytogenetic location of TOF copy number variant identified in Table 1 ; Gene, name of reference gene within TOF CNV according to build 36.1 of the human reference genome; Tag count, number of sense tags mapped to reference gene from four separate human right ventricular outflow tract mRNA expression libraries, expressed as mean ± s.d. For loci containing a known disease-associated gene (bold), the expression profile for only that gene is shown. Proband, individual subject identification number; CNV, cytogenetic location of copy number variant; CN, copy number; Age, current age (and age at diagnosis) in years; Sex, female (F) or male (M).
malformations 7 . Mice engineered to lack components of the NOTCH1 signaling pathway have TOF-like phenotypes 31 . Our findings provide direct evidence for NOTCH1 mutations in TOF. JAG1 mutations are known to cause TOF in the context of Alagille syndrome and in isolation 4, 32 . The individual with the 4-Mb de novo deletion of JAG1 identified here has no clinical features of Alagille syndrome. The discovery of CNVs altering NOTCH1 and JAG1 underscores the need to assess gene dosage in mutation analyses of congenital heart diseaseassociated genes. Four other loci were altered by CNVs in a single individual with TOF. CNVs at these candidate TOF loci occurred at a low frequency similar to those of NOTCH1 and JAG1 mutations, emphasizing the genetic heterogeneity of TOF. Three genes are encoded at the 2p23.3 locus: RAB10, KIF3C and ASXL2. Although none have been previously implicated in cardiac development, each is expressed in the RVOT ( Table 2 ). The expression of RAB10, which encodes a GTPase, is highest. Because KRAS, another GTPase, is activated by Noonan syndrome mutations 33 , RAB10 is a promising candidate gene in TOF.
Pathogenicity of a 1.8-Mb de novo duplication at 2p15 found in one TOF case is likely, given its size and the absence of CNVs at this locus in all controls. Of 12 genes located in the duplicated interval, 9 are expressed in the human RVOT ( Table 2 ) and none were previously implicated in cardiogenesis. The 4q22.1 deletion encompasses PPM1K, and its transcripts, encoding a phosphatase, are present in RVOT tissues. The deletion at 10q11.21 contains no known genes or coding or noncoding RNAs.
In summary, our studies defined seven new loci that substantially increase risk (odds ratio Z 8.9) for sporadic, nonsyndromic TOF. Although some loci are large (4100 kb) and three loci showed incomplete penetrance, expression data from human RVOT highlights a subset of genes that should be prioritized in future studies. Moreover, the data identified de novo CNVs at 10 loci, accounting for 10% of TOF in our case series, which explains sporadic presentation and defines genetic heterogeneity in this serious heart malformation.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
ONLINE METHODS
Study subjects. Individuals with TOF and their parents at Brigham & Women's Hospital, Children's Hospital Boston and the Instituto do Coração da Universidade de São Paulo, Brazil provided informed consent for participation in these studies, which were performed in accordance with institutional guidelines. TOF was diagnosed based on noninvasive imaging (two-dimensional echocardiography and/or MRI) and/or invasive studies (cardiac catheterization and/or surgery). TOF cases with clinical features of developmental syndromes, multiple major developmental anomalies or major cytogenetic abnormalities were excluded. When 22q11.2 analyses (routinely obtained on all Boston subjects and obtained when clinically indicated on Brazilian subjects) revealed microdeletion, subjects were excluded. TOF parents had neither significant congenital or cardiac disease. Control subjects were assembled from the BRASS 15 cohort (n ¼ 538), subjects with multiple sclerosis (n ¼ 934) and healthy controls (n ¼ 271) collected from Brigham & Women's Hospital and unrelated parents of individuals with TOF (n ¼ 228). Control trios were assembled from HapMap CEU and YRI subjects (n ¼ 165) and South American controls (n ¼ 129). Control subjects and trios had neither significant congenital nor cardiac disease.
Genotyping and identification of CNVs. Genotyping was performed using the Affymetrix Human Genome-Wide SNP Array 6.0 at the Broad Institute (TOF trios and controls) and Affymetrix (HapMap trios). Genotypes from X and Y chromosomes were excluded from analyses. Initially 121 TOF trios and 98 control trios were analyzed using Birdseed version 1.5 with 97.8 ± 1.3% and 99.7 ± 0.6% average call rates achieved, respectively ( Supplementary Fig. 1 ). There was no evidence of nonpaternity (determined by the number of mendelian errors present in each trio as calculated by PLINK 34 ) in the trios used. Genotype information on the CEU and YRI HapMap trios was obtained directly from Affymetrix. The Birdseye 13 CNV-detection algorithm was used to identify de novo CNVs in trios using a confidence (lod) score of 10 10 for the proband to be copy number (CN) variable (CN ¼ 0, 1, 3 or 4) and a lod score of 10 6 for the parents to be copy-number variable. This was done in order to maximize the probability that the child truly possessed a de novo CNV. CNVs in proband samples that were absent from both parental samples were considered putative de novo CNVs. Those putative de novo CNVs that corresponded to known copy number polymorphisms (CNPs) 14 or that were smaller than 20 kb were discarded. De novo CNVs with Z 50% overlap with CNVs found in Z 0.1% of 2,265 control samples were designated CNPs. When an excessive number of de novo CNVs (43 s.d. above the mean number of CNVs per individual) was identified, subjects were excluded from analyses. CNVs due to cell-line artifacts (see main text) were identified in HapMap samples and were discarded 16 . CNV locations are based on the March 2006 human reference sequence (US National Center for Biotechnology Information (NCBI) build 36.1). For non-trio controls, CNV calls were based on Birdseye using a lod score of 10 10 to be copy-number variable (CN ¼ 0, 1, 3 or 4) .
Multiplex ligation-dependent probe amplification (MLPA). At least two independent MLPA probes (Supplementary Table 3 ) corresponding to sequences encompassed by CNVs were designed to confirm each de novo CNV in samples from subjects with TOF and parents and to identify new CNVs at these loci (excluding chromosome 22q11.2 deletions) in a screen of a second cohort of 398 subjects with TOF. Synthetic oligonucleotide probes with a final product size of 90-160 bp (including universal sequences) were designed from genomic sequences (March 2006 human reference sequence, NCBI build 36.1). Probe design sought to maximize unique hybridization using the BLAT program (http://genome.ucsc.edu), a T m 4 65 1C and G+C content
